Translating Research Into Practice
Aspirin and Decreased Colon Cancer Risk: Challenges Interpreting a Large Prospective Trial
Rita Wickham, PhD, RN, AOCN®
Independent Oncology and Palliative Care Consultant
Author’s disclosures of potential conflict of interest are found at the end of this article.
Correspondence to: Rita Wickham, PhD, RN, AOCN®. E-mail: firstname.lastname@example.org
J Adv Pract Oncol 2012;3:399–405 |
DOI: 10.6004/jadpro.2012.3.6.7 |
© 2012 Harborside Press®
In late 2011, Burn et al. published updated results on the CAPP2 trial in The Lancet. CAPP2 investigated the effects of daily aspirin on patients with Lynch syndrome, also known as hereditary nonpolyposis colorectal cancer. The two related articles in this issue provide an overview of CAPP2 as well as a perspective on the challenges of interpreting a large prospective trial.
For access to the full length article, please sign in